Blood Cancer News and Research

RSS

Simple blood test may predict CAR-T therapy success in multiple myeloma

A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according to new research from Weill Cornell Medicine, NewYork-Presbyterian, Columbia University and Icahn School of Medicine at Mount Sinai.

24 Jul 2024

$Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia$

Novel therapy can improve the prognosis of relapsed/refractory acute myeloid leukemia

Relapsed/refractory acute myeloid leukemia (AML), a so-called blood cancer, has an extremely poor prognosis because of resistance to anti-cancer drugs and frailty of the patient's organ functions.

18 Jul 2024

Blood cancer drug could help improve the efficiency of radiotherapy in meningiomas

Drugs developed to fight blood and other cancers could also help improve the efficiency of radiotherapy in the most commonly diagnosed low-grade brain tumour in adults, a new study has found.

10 Jul 2024

Regular IgG monitoring and replacement therapy reduce severe infections in CLL and NHL patients

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with those who didn't, according to a study published in Blood Advances.

21 Jun 2024

Artificial variants of Withanolides act highly specifically against leukemia cells

Nightshade plants produce a diverse array of compounds with therapeutic potential. Researchers at CeMM have now identified an artificial variant inspired by the Withanolides group that acts highly specifically against leukemia cells.

21 Jun 2024

MEK inhibitor trametinib shows potential in pediatric JMML treatment

The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II clinical trial, with seven of 10 patients alive after a median of two years.

13 Jun 2024

Study identifies genetic predictors of X chromosome loss in aging women

Researchers have identified inherited genetic variants that may predict the loss of one copy of a woman's two X chromosomes as she ages, a phenomenon known as mosaic loss of chromosome X, or mLOX.

12 Jun 2024

Enhancing CAR-T cell therapy with biodegradable scaffolds

CAR-T cell therapies are transforming the treatment of previously incurable blood cancers. Six approved CAR-T products have been administered to more than 20,000 people, and more than 500 clinical trials are underway.

12 Jun 2024

UC San Diego Health launches personalized immunotherapy for metastatic melanoma

UC San Diego Health is the first hospital system in the region to offer a new immunotherapy treatment for metastatic melanoma.

4 Jun 2024

Targeting metabolic pathways to combat Epstein-Barr virus infections

The Epstein-Barr virus can cause a spectrum of diseases, including a range of cancers.

24 May 2024

Evolving treatment paradigms in multiple myeloma could improve patient outcomes

The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy agent.

24 May 2024

Exercise enhances efficacy of antibody therapy in leukemia patients

Bouts of moderate-to-vigorous intensity exercise could improve the efficacy of antibody therapies used to treat chronic lymphocytic leukemia, new research has shown.

21 May 2024

AML patients at the extremes of older age derive benefit from VEN-HMA regimen

Standard of care treatment for acute myeloid leukemia (AML) is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival.

9 May 2024

Enhancing the ability of natural killer cells to combat hematologic malignancies

A new study reveals a groundbreaking approach to immunotherapy, demonstrating that blocking the interaction between the CD300A receptor and phosphatidylserine (PS) significantly enhances the ability of human natural killer (NK) cells to lyse hematologic malignancies (HMs).

9 May 2024

Novel vaccine approach targets AML and other blood cancers

Acute myeloid leukemia (AML) is a type of blood cancer that forms in the soft marrow of the bones, typically attacking cells that would otherwise form the key component of the body's immunodefense system, white blood cells.

3 May 2024

NK cells' role in cancer therapy resistance unveiled

Activated T cells that carry a certain marker protein on their surface are controlled by natural killer (NK) cells, another cell type of the immune system.

3 May 2024

Exposed to agent orange at US bases, veterans face cancer without VA compensation

As a young GI at Fort Ord in Monterey County, California, Dean Osborn spent much of his time in the oceanside woodlands, training on soil and guzzling water from streams and aquifers now known to be contaminated with cancer-causing pollutants.

29 Apr 2024

Study sheds light on the significance of glucocorticoid receptor in drug-resistant prostate cancer

New research from the University of Eastern Finland sheds light on the significance of the glucocorticoid receptor in drug-resistant prostate cancer, showing that the development of drug resistance could be prevented by limiting the activity of coregulator proteins.

10 Apr 2024

Research identifies how leukemia develops resistance to first line treatments

Relapses in a common form of leukemia may be preventable following new research which has identified how the cancer develops resistance to first line treatments.

9 Apr 2024

Study evaluates the feasibility of discontinuing CLL specialist care

A study published today in Blood Advances showed that among patients in Denmark who had slow-growing chronic lymphocytic leukemia (CLL) with no symptoms and a low risk for ever needing treatment, those who stopped seeing their doctors for specialized follow-up had fewer hospital visits, fewer infections, and similar survival after three years compared to those who continued to undergo specialized follow-up.

4 Apr 2024